Thema: US92764N1028
VIR, US92764N1028
stock-6690192_1920.jpg - Foto: THN
Vir Biotechnology stock gets oncology boost from Gilead deal
Vir Biotechnology stock is in focus after Gilead agreed to collaborate on three masked T-cell engagers for solid tumors. The deal expands Vir's oncology pipeline.
ad-hoc-news.de, heute 00:07 Uhr
VIR, US92764N1028
Vir Biotechnology stock: Gilead deal brings up to USD 135 ...
Vir Biotechnology entered a three-candidate Gilead deal on October 14, 2026. For Vir Biotechnology stock, results are due November 4, 2026.
ad-hoc-news.de, 24.10.26 01:40 Uhr
VIR, US92764N1028
Vir Biotechnology enters Gilead deal: what it means for ...
Gilead deal offers Vir Biotechnology stock up to USD 135 million upfront. Three candidates are due for a November 8, 2026 data event.
ad-hoc-news.de, 16.10.26 04:44 Uhr
VIR, US92764N1028
Raymond James reiterates USD 19.00 target for Vir Biotechnology ...
Vir will present hepatitis delta data on November 8, 2026. Eight analysts give Vir Biotechnology stock a USD 21.57 average target in consensus.
ad-hoc-news.de, 06.10.26 05:31 Uhr
VIR, US92764N1028
Raymond James reiterates USD 19.00 target for Vir Biotechnology ...
Revenue hit USD 238.95 million in the second quarter, up 19,582.50 percent year over year. Vir Biotechnology stock has USD 1.9 billion market cap.
ad-hoc-news.de, 01.10.26 12:00 Uhr
